The National Institute on Drug Abuse (NIDA) seeks research for the discovery and development of medications to prevent and treat substance use disorders (SUDs) and overdose.
The UG3/UH3 Phased Innovation Awards Cooperative Agreement funding mechanism involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases.
Application may include preclinical or clinical research studies that will have high impact and quickly yield the necessary results to advance closer to or to FDA approval. The compounds to be evaluated can be small molecules or biologic and may focus on the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications.
Through this funding opportunity, NIDA seeks to fast-track the discovery and development of medications to prevent and treat SUDs and overdose and to advance them in the FDA's pathway.
Deadlines:
- Letter of Intent Due Date(s): 30 days prior to the application due date
- Application Due Date(s): April 10, 2025; Aug. 11, 2025
- AIDS Application Due Date(s): April 10, 2025; Aug. 11, 2025
PAR-25-329 Expiration Date August 12, 2025
Application budgets are limited to $3 million per year for direct costs.
The maximum period of support is 5 years.